For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Colgate-Palmolive Company (CL) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Low · Gem Score -21 (−100…+100 Quality+Value blend) · Quality 44 · Value -75 · Sentiment -13 (timing only, not weighted)
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Colgate-Palmolive Company
CL NYSEColgate-Palmolive Company is an American multinational consumer products company. It focuses on the production and distribution of oral care, personal care, home care, and pet nutrition products for consumers worldwide. In oral care, Colgate-Palmolive offers toothpaste, toothbrushes, mouthwashes, and professional dental products under well-known global brands such as Colgate, Darlie, elmex, hello, meridol, Sorriso, and Tom’s of Maine. Its personal and home care portfolio includes liquid and bar soaps, shower gels, shampoos, conditioners, deodorants, dishwashing liquids, household cleaners, fabric conditioners, and skin health products marketed under brands like Palmolive, Softsoap, Irish Spring, Speed Stick, Ajax, Fabuloso, Murphy, Protex, Sanex, Soupline, and Suavitel. Through Hill’s Science Diet and Hill’s Prescription Diet, the company provides specialized pet nutrition products distributed via pet retailers, veterinarians, and e-commerce platforms. Headquartered in New York City, Colgate-Palmolive serves more than 200 countries and territories, playing a central role in the global consumer staples sector with extensive retail, wholesale, veterinary, and online distribution networks.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 2.63
Total Equity: $365.00M
Shares: 811,100,000
Total Debt: $7.99B
Cash: $1.29B
EBITDA: $3.94B
Total Debt: $7.99B
Cash: $1.29B
Revenue: $20.38B
Revenue: $20.38B
Revenue: $20.38B
Total Equity: $365.00M
Tax Rate: 26.1%
Equity: $365.00M
Total Debt: $7.99B
Cash: $1.29B
Current Liabilities: $6.85B
Long-Term Debt: $6.87B
Total Debt: $7.99B
Total Equity: $365.00M
Shares: 811,100,000
Shares: 811,100,000
CapEx: -$564.00M
Shares: 811,100,000
Stock Price: $92.76
Net Income: $2.13B
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 11, 2026 2:34pm (12d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $17.4B | $18.0B | $19.5B | $20.1B | $20.4B |
| Cost of Revenue | $7.0B | $7.7B | $8.1B | $7.9B | $8.1B |
| Gross Profit | $10.4B | $10.2B | $11.3B | $12.2B | $12.3B |
| Operating Expenses | $7.0B | $7.4B | $7.3B | $7.9B | $8.9B |
| Operating Income | $3.3B | $2.9B | $4.0B | $4.3B | $3.3B |
| Net Income | $2.2B | $1.8B | $2.3B | $2.9B | $2.1B |
| EBITDA | $3.9B | $3.4B | $4.6B | $4.9B | $3.9B |
| EPS | $2.56 | $2.13 | $2.78 | $3.53 | $2.64 |
| EPS (Diluted) | $2.55 | $2.13 | $2.77 | $3.51 | $2.63 |
Balance Sheet (Annual)
Last updated: Aug 11, 2026 12:26pm (12d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $832.0M | $775.0M | $966.0M | $1.1B | $1.3B |
| Total Current Assets | $4.4B | $5.1B | $5.3B | $5.3B | $5.7B |
| Total Assets | $15.0B | $15.7B | $16.4B | $16.0B | $16.3B |
| Current Liabilities | $4.1B | $4.0B | $4.7B | $5.8B | $6.9B |
| Long-Term Debt | $7.2B | $8.7B | $8.2B | $7.3B | $6.9B |
| Total Liabilities | $14.1B | $14.9B | $15.4B | $15.5B | $16.0B |
| Total Equity | $971.0M | $806.0M | $957.0M | $544.0M | $365.0M |
| Retained Earnings | $24.4B | $24.6B | $25.3B | $26.1B | $26.6B |
Cash Flow (Annual)
Last updated: Aug 11, 2026 2:34pm (12d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $3.3B | $2.6B | $3.7B | $4.1B | $4.2B |
| Capital Expenditure | -$567.0M | -$696.0M | -$705.0M | -$561.0M | -$564.0M |
| Free Cash Flow | $2.8B | $1.9B | $3.0B | $3.5B | $3.6B |
| Acquisitions (net) | $0 | -$809.0M | $0 | $0 | -$293.0M |
| Net Debt Issued / (Repaid) | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$1.3B | -$1.3B | -$1.1B | -$1.7B | -$1.2B |
| Net Change in Cash | -$56.0M | -$57.0M | $191.0M | $130.0M | $192.0M |
Growth Trends (YoY %)
Last updated: Aug 11, 2026 2:34pm (12d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +3.1% | +8.3% | +3.3% | +1.4% |
| Gross Profit Growth | -1.2% | +10.5% | +7.4% | +0.7% |
| Operating Income Growth | -13.2% | +37.7% | +7.1% | -22.5% |
| Net Income Growth | -17.6% | +28.9% | +25.6% | -26.2% |
| EBITDA Growth | -11.6% | +32.4% | +7.1% | -19.2% |
Dividend History (Last 20)
Last updated: Aug 11, 2026 12:26pm (12d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-07-20 | $0.53 | — | — | — |
| 2026-04-20 | $0.53 | — | — | — |
| 2026-01-21 | $0.52 | — | — | — |
| 2025-10-17 | $0.52 | — | — | — |
| 2025-07-18 | $0.52 | — | — | — |
| 2025-04-17 | $0.52 | — | — | — |
| 2025-01-21 | $0.50 | — | — | — |
| 2024-10-18 | $0.50 | — | — | — |
| 2024-07-19 | $0.50 | — | — | — |
| 2024-04-19 | $0.50 | — | — | — |
| 2024-01-19 | $0.48 | — | — | — |
| 2023-10-20 | $0.48 | — | — | — |
| 2023-07-20 | $0.48 | — | — | — |
| 2023-04-20 | $0.48 | — | — | — |
| 2023-01-20 | $0.47 | — | — | — |
| 2022-10-20 | $0.47 | — | — | — |
| 2022-07-20 | $0.47 | — | — | — |
| 2022-04-20 | $0.47 | — | — | — |
| 2022-01-21 | $0.45 | — | — | — |
| 2021-10-20 | $0.45 | — | — | — |
Deep Analysis
Narrative Economics
market-narrative step).
AI Lens 4th lens · how AI reaches this business · 5-yr
2026-08-11Advertising and promotion is Colgate's largest discretionary cost line; generative creative, automated localization across ~200 markets, and AI-driven trade-promotion and pricing optimization can hold share of voice while cutting spend per market — a direct route to the SG&A line that produced 2024's 21% operating margin.
If shopping shifts to AI agents that optimize on price-per-unit, ingredient equivalence and reviews, decades of brand-recall advertising loses its transmission channel and the branded premium in oral and home care compresses toward private label — the one mechanism that could genuinely dent 60% gross margin.
Whether LLM/agent-mediated purchasing becomes a material share of household replenishment and whether brand or spec wins inside it. Observable: organic growth split between price and volume in developed markets, and private-label share in US oral care and dish.
Physical route-to-market into millions of small-format outlets across India, Brazil, Mexico and Africa, dentist/professional endorsement networks, and manufacturing-plus-shelf scale — none of which cheap intelligence conjures.
AI Lens thesis
Colgate's value sits in habit, brand recall, dentist endorsement and physical distribution — all outside the information-processing layer AI attacks, so exposure is genuinely low; AI reaches the P&L mainly through cost (creative, media buying, demand forecasting, revenue growth management, back-office in a global admin footprint) and only secondarily through demand (agentic commerce reweighting choice toward specs and price, plus AI-lowered costs of launching credible DTC challenger brands). The net is modestly positive because Colgate captures cost savings in a category where willingness-to-pay is anchored by habit rather than by information asymmetry, but the upside is capped: peers get the same tools, retailers hold the transaction data, and any savings competed away lands back in promotional intensity.
What the market may be underestimating
Upside Revenue growth management — AI-driven pack-price architecture across hundreds of SKUs and currencies — is where Colgate has historically defended margin through devaluation cycles; cheap inference makes that capability continuous rather than annual, which is worth more than any consumer-facing AI feature.
Downside AI collapses the cost of brand creation: formulation contract manufacturers plus AI creative and targeting let credible niche oral/pet brands reach scale in specific channels, fragmenting the top of the category exactly where Colgate's premium mix (elmex, Tom's, Hill's-adjacent pet nutrition) earns its margin.
Outcome range spread 34
Claude Reading
Looking at the raw quarterly tape first: revenue has crept from $5.06B (Q2'24) to $5.32B (Q1'26) — that's ~5% cumulative over seven quarters, or roughly 3% annualized. Nothing accelerating. Net income is more troubling: Q4'25 printed -$36M (a charge/impairment quarter), and even excluding it, the run rate of $690-745M per quarter is flat-to-down vs. the $731-738M range a year earlier. TTM net income around $2.09B against $92.75 price and ~800M shares implies ~$2.60 EPS and a ~35x P/E on a business growing revenue 2-3% and earnings not at all. FCF at $3.63B is the one genuinely bright number — 4.9% FCF yield on market cap, covering the 2.3% dividend nearly 2x. But debt/equity of 21.9x isn't "extreme leverage" as market-forces claims — equity is depressed by decades of buybacks. Net debt/EBITDA is roughly $6.7B / $4.3B ≈ 1.6x, which is normal for staples. The market-forces model is overstating this.
On the model stack: the synthesis fair value of $53 (implying 43% downside) strikes me as too aggressive for a business generating $3.6B in FCF with a durable brand portfolio. A reverse DCF at $92.75 with 10% discount and 3% terminal growth implies roughly 4-5% FCF growth for a decade — not heroic given Hill's Pet Nutrition and EM oral care. Even at a stricter 8% discount and 2.5% growth, fair value lands closer to $70-75, not $53. The narrative model's split ($53 fundamentals + $39 "safety premium") is directionally right but mis-weighted; I'd call it $70 fundamentals + $22 premium. So I partially agree with "overvalued" but strongly dissent on magnitude. The pre-flight framing as "dividend-income" is correct; the classification "mature_earner" is correct; the market-forces "short on rallies to $100" call is overconfident given a 4.9% FCF yield floor.
The contrarian case the models are underweighting: Colgate has posted 60.1% gross margins — near a decade high — and Hill's Pet is a genuine growth engine (mid-to-high single digits, higher margins than the base). GLP-1 fears hit food/snacks, not toothpaste and pet food. The dollar strength drag on 70%+ international revenue is cyclical, not structural, and a weaker USD in 2026-27 would flatter reported growth by 200-400bps without any operational change. Q4'25's negative NI looks like a one-time charge (likely Argentina hyperinflation accounting or restructuring), not a trend break — Q1'26 snapped back to $646M and 12.1% margin. Insider activity is genuinely neutral: small option-exercise-and-sell patterns are administrative, not a signal. Where I do side with the bears: at 35x reported earnings and 21x EV/EBITDA, you're paying a premium multiple with a -3.7% earnings CAGR and 1.4% recent revenue YoY. That's the definition of multiple compression risk if the safety bid unwinds.
Data thinness worth flagging: the P/B of 206 is a buyback artifact, not a red flag — ignore it. ROIC of 34.6% is the number that actually matters and confirms the business quality. The 2026-03-31 quarter is the most recent print; we're implicitly trusting a full year of forward data given the file's dating. If the file's timestamps are correct, we have very fresh data and the deceleration story is real, not stale. My verdict: overvalued but not dramatically so — the synthesis's $53 target is a bear-case floor, not a base case. Fair value is $70-78 assuming 3% top-line, stable margins, and continued buybacks; you get there in a garden-variety multiple compression to 27-28x forward earnings. At $92.75 you're paying ~20% above what the numbers support, and the FCF yield + dividend gives you a real ~7% total return floor even from here, which is why I'm not table-pounding short. Wait for $75-78 for a starter; avoid chasing above $95.
GPT Reading
What jumps out first is that Colgate is not being valued on the business it reported in 2025; it is being valued on the idea of permanence. The underlying operating profile is respectable but plainly mature. Revenue went from $17.4B in 2021 to $20.4B in 2025, only about 4% annualized, and the most recent quarterly growth was just 8.3% year over year in Q1 2026 ($5.32B vs $4.91B) against an easy compare after a messy 2025. More importantly, earnings quality looked worse than the revenue line: 2025 net income fell to $2.13B from $2.89B in 2024 despite sales rising to $20.38B from $20.10B. That is a sharp drop in net margin from 14.4% to 10.5%, and the quarterly series makes clear this was not a smooth year: three quarters in the mid-14% net margin range, then a Q4 loss of $36M. If that Q4 was driven by one-time charges, the annual P/E of 35x overstates underlying earnings; but if investors are willing to normalize away every ugly quarter, they also need to explain why a business growing low single digits deserves 3.7x sales and 20.8x EBITDA.
The positive case in the raw numbers is that this remains a very cash-generative franchise. Gross margin stayed excellent at 60.1% in 2025, operating cash flow was $4.20B, and free cash flow was $3.63B on only $564M of capex. That is the kind of capital-light model staples investors pay for. On a market cap of $74.3B, though, that FCF is only about a 4.9% yield before asking whether growth can accelerate. That is not obviously compelling for a company with 2.4% revenue CAGR and negative earnings CAGR over the last several years. The balance sheet also deserves more skepticism than the “safe haven” label usually gets. Total debt is $7.99B against just $1.29B of cash, and equity is only $365M, which makes the headline P/B and debt/equity ratios almost useless in a conventional sense but still tells you there is very little book cushion. A current ratio of 0.83 is not alarming for staples, yet it reinforces that this is a finely tuned cash machine, not a fortress in the balance-sheet sense.
I land bearish mainly because the market appears to be paying peak-quality multiples for a business that has recently shown sub-peak profitability. On 2024 earnings, the stock would have looked closer to 26x net income; on 2025 reported earnings it is 35x; on free cash flow it is still over 20x. None of those are disaster valuations for a high-quality consumer staple, but they are rich when recent fundamentals are not cleanly trending upward. Quarterly revenue has hovered around $5.0B-$5.3B for eight quarters, which says stability, not compounding. The latest quarter’s net margin of 12.1% is still below the 14%-15% range seen through most of 2024 and 2025 before the Q4 break. So the market is effectively asserting that Colgate will both restore margins and maintain the safety premium indefinitely. At $92-93, that leaves little room for anything less than near-flawless execution. I can justify a premium multiple for Colgate; I cannot justify this much premium on these numbers.
The strongest case against my view is straightforward: 2025 may simply be a bad accounting year that masks a healthier business. If Q4’s $36M loss was dominated by restructuring, tax, or impairment items, then the true earnings power is closer to the roughly $700M per quarter Colgate earned in the surrounding periods. Annualizing something like $700M-$740M per quarter gets you nearer $2.8B-$3.0B of earnings power, which makes today’s price look more like high-20s P/E for a category leader with a 60% gross margin, 17%-plus normalized operating margin, and very dependable cash conversion. That is expensive, but not crazy for a global staples franchise with pet nutrition exposure, emerging-market reach, and a long record of returning cash. A smart bull would also point out that Q1 2026 rebounded to $646M of profit on $5.32B of revenue, suggesting 2025’s annual drop may not reflect a new baseline. I weigh that less heavily because even the rebound quarter did not restore the old 14%-15% net margin profile, and because the market already prices in normalization rather than giving investors a discount for uncertainty.
What would change my mind is not another abstract “quality” argument but a cleaner earnings bridge. If the next two to three quarters show revenue holding above $5.3B and net margins back sustainably above 14%, then annual earnings power moves back toward $2.8B-$3.0B and the current price starts to look merely full rather than stretched. I would also become less negative if free cash flow can move above $4.0B without leverage rising further, because that would support the premium with actual owner earnings rather than narrative. Conversely, if sales remain around the current run rate while margins stay in the 12%-13% range, then the stock is too expensive even for a defensive name, and a derating toward the mid-$70s would be more appropriate.
Grok Reading
The raw numbers on Colgate-Palmolive describe a high-quality cash machine whose earnings power is quietly eroding while the market still pays a scarcity premium for the brand. Annual revenue crawled from $20.10B in 2024 to $20.38B in 2025 (+1.4%), consistent with the 2.4% multi-year CAGR, and the latest quarter ($5.32B) continues that low-single-digit trajectory. What stands out is the profit collapse underneath: operating income fell from $4.27B to $3.31B, net income from $2.89B to $2.13B, and the December 2025 quarter printed a $36M loss that dragged the annual net margin to 10.5% from the mid-teens that had been routine. Even the March 2026 rebound to $646M net income only restored a 12.1% margin—still well below the 14–15% run-rate of 2024. Free cash flow remains the bright spot at $3.63B on just $564M of capex, confirming the capital-light franchise, but that cash is being generated by a business whose earnings CAGR is already negative 3.7%.
The balance sheet explains why the equity metrics look absurd. With only $365M of book equity against $7.99B of debt, the 206× P/B and 21.9× debt-to-equity ratios are not data errors; they are the arithmetic consequence of years of buybacks and dividends that have hollowed out the equity account while leverage stays elevated and the current ratio sits at 0.83. At 35.3× trailing earnings, 20.8× EV/EBITDA and a 2.3% dividend yield, the $92.76 price is capitalizing the FCF stream as if mid-single-digit growth and margin recovery were assured. The models’ $53–64 fair-value range is directionally correct: investors are paying roughly a 40–70% premium for narrative safety rather than for the growth the income statement is actually delivering.
The strongest counter-argument is that the franchise still works. Gross margin held at 60.1%, FCF conversion is excellent, oral-care and pet-nutrition categories retain pricing power, and the emerging-market volume base has historically absorbed developed-market softness. A skeptic of the bear case would note that the 2025 earnings drop may contain one-time charges (the single negative quarter is the obvious culprit), that sequential revenue has stabilized and ticked higher into early 2026, and that a 4.9% FCF yield on the current enterprise is not catastrophic for a defensive compounder when macro uncertainty is high. Insiders are not dumping stock in size, and the dividend has institutional and retail bid support that can keep the multiple elevated longer than a pure DCF would imply. Those points are real; they simply do not justify 35× earnings on a business whose recent earnings growth is sharply negative and whose organic top-line is stuck near 2%.
I would reverse to neutral or constructive only if operating margin reclaimed the mid-teens on a run-rate basis for two consecutive quarters, if full-year net income moved back above $2.8B, or if revenue growth sustained above 4% with clear volume contribution rather than pure price. A material reduction in net leverage that rebuilds book equity would also reduce the fragility premium currently embedded in the capital structure. Until those prints appear, the stock screens as a bond proxy priced like a growth compounder.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Revenue has compounded steadily from $17.42B (2021) to $20.38B (2025), with gross margin recovering from a 57.0% trough in 2022 to 60.1% in 2025. FCF has grown every year to $3.63B, and OCF/NI of 1.6x with accruals at -8.3% of assets plus a Beneish M of -3.01 and Altman Z of 6.9 point to genuinely high-quality earnings. Diluted shares fell from 848.3M to 811.1M (-1.1% CAGR) with buybacks running nearly 10x SBC, so per-share economics are being actively protected. The clear blemish is 2025 operating margin collapsing to 16.2% from 21.2% in 2024, and net income falling to $2.13B from $2.89B despite revenue and FCF still growing - implying a large non-cash or one-time charge (restructuring, impairment, or legal) rather than operational rot, but it deserves verification. Balance sheet is a constraint not a cushion: $1.40B cash against $6.59B net debt, though $3.63B annual FCF easily services it. Insider tape is neutral-to-slightly-negative (sales and tax withholdings, no open-market buys), typical for a mature large-cap. Overall this is a durable, well-run staples business with a real brand moat implied by sustained 60% gross margins, but not a fortress given the leverage and the unexplained 2025 margin gap.
Verify before trusting this (5)
- Nature of the 2025 operating margin drop - restructuring charge, goodwill/intangible impairment, litigation reserve, or genuine cost pressure?
- Debt maturity ladder and weighted cost - is the $6.59B net debt fixed at favorable rates?
- Category and geographic mix - Hill's Pet Nutrition vs Oral Care contribution and any concentration risk
- Volume vs price decomposition of revenue growth to test whether pricing is masking volume weakness
- Pension and other off-balance-sheet obligations given the mature workforce
The composite fair value of $64.01 and signal-adjusted FV of $53.32 both sit materially below the $92.62 price, implying the market is capitalizing Colgate as a forever-compounder with reliable pricing power and EM/pet tailwinds. The DCF ($76.65) is the most generous method and still leaves ~17% downside; the EPV floor ($44.55) and anchored PE ($58.19) tell you the underlying earnings power, absent heroic growth, supports something in the $50s-low $60s. Earnings quality is clean so no haircut is warranted, and the Strong business grade justifies pushing deserved value toward the DCF end of the range - call it mid-$60s to low-$70s on a generous read. Even at the top of that range, today's price offers no margin of safety; you are underwriting continued mid-single-digit growth, stable ~20%+ operating margins (despite the 2025 wobble), and buyback-driven per-share compounding indefinitely. That's a plausible base case, not a bargain. This is the classic 'good company, full price' setup - the market already knows Colgate is a fortress. To get interested on valuation alone, I'd want the price closer to the composite FV with a real cushion below it.
Verify before trusting this (4)
- Whether the 2025 operating-margin gap is one-time cleanup or structural category pressure
- Organic volume trends in developed markets vs price/mix contribution
- Forward guidance on EM growth and Hill's Pet segment margins
- FX and input-cost assumptions embedded in the DCF
Colgate sits in the eye of the storm: the tape is mildly risk-on (VIX 15.5, S&P near highs), but with a beta of 0.33 that tailwind barely reaches this name - defensives are exactly the cohort that gets left behind when money is chasing risk. The offset is a durable, low-cult 'steady-compounder / dividend aristocrat' narrative that continues to justify a premium multiple; investors are explicitly paying for predictability, and that story has not cracked. On the flow side, the Q2 print drew a cautious market response - revenue in-line, modest EPS beat, but analyst questions skewed toward volume softness and mix. That is a quiet, not loud, headwind - the kind that caps upside rather than forcing a de-rating. Insider option-exercise selling by a director is a nothing-burger. Macro cross-currents (higher 10y at 4.65%, Iran-driven oil disruption threatening input costs, softer China PPI easing some COGS pressure) roughly wash. Net: no dominant force in either direction on this specific name right now.
Verify before trusting this (4)
- Whether sell-side revises FY targets down after the cautious Q2 read - would tip the balance to headwind
- Sustained risk-on rotation extending beyond 2-3 weeks (would widen defensive underperformance)
- Any crack in the dividend-aristocrat narrative (payout coverage chatter, capital-allocation shift)
- 10y yield direction - a move back toward 4.2% would relieve pressure on the premium multiple
Colgate's value sits in habit, brand recall, dentist endorsement and physical distribution — all outside the information-processing layer AI attacks, so exposure is genuinely low; AI reaches the P&L mainly through cost (creative, media buying, demand forecasting, revenue growth management, back-office in a global admin footprint) and only secondarily through demand (agentic commerce reweighting choice toward specs and price, plus AI-lowered costs of launching credible DTC challenger brands). The net is modestly positive because Colgate captures cost savings in a category where willingness-to-pay is anchored by habit rather than by information asymmetry, but the upside is capped: peers get the same tools, retailers hold the transaction data, and any savings competed away lands back in promotional intensity.
Verify before trusting this (8)
- Emerging-market direct store coverage
- Professional/dentist endorsement programs
- Retail shelf-space negotiations and slotting
- Category unit volumes in developed markets
- Emerging-market per-capita consumption trends
- Oral care penetration in India/Africa
- SG&A as % of sales trajectory
- Gross margin vs 2024's 60.5% peak
This lens hasn't been run for this ticker yet.
Prediction unavailable. valuation-synthesis has no result for CL — the prediction needs its fair-value anchors.